OMER vs. MLTX
OMER (Omeros Corporation) and MLTX (MoonLake Immunotherapeutics) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, OMER returned -7.74%/yr vs 16.38%/yr for MLTX. At a 0.18 correlation, their price movements are largely independent.
Performance
OMER vs. MLTX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, OMER achieves a -39.85% return, which is significantly lower than MLTX's 68.13% return.
OMER
- 1D
- 0.49%
- 1M
- -9.86%
- YTD
- -39.85%
- 6M
- 8.62%
- 1Y
- 221.81%
- 3Y*
- 23.46%
- 5Y*
- -7.74%
- 10Y*
- 0.05%
MLTX
- 1D
- 15.36%
- 1M
- 21.83%
- YTD
- 68.13%
- 6M
- 64.27%
- 1Y
- -49.06%
- 3Y*
- -5.04%
- 5Y*
- 16.38%
- 10Y*
- —
OMER vs. MLTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
OMER Omeros Corporation | -39.85% | 73.84% | 202.14% | 44.69% | -64.85% | -54.99% | 28.93% |
MLTX MoonLake Immunotherapeutics | 68.13% | -75.66% | -10.33% | 475.14% | 6.17% | -13.02% | 11.91% |
Correlation
The correlation between OMER and MLTX is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Oct 20, 2020 | 0.18 |
Fundamentals
OMER:
$656.06M
MLTX:
$1.58B
OMER:
-$0.05
MLTX:
-$3.90
OMER:
$0.00
MLTX:
$0.00
OMER:
-$10.29M
MLTX:
-$1.49M
OMER:
-$110.44M
MLTX:
-$179.84M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
OMER vs. MLTX — Risk / Return Rank
OMER
MLTX
OMER vs. MLTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Omeros Corporation (OMER) and MoonLake Immunotherapeutics (MLTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| OMER | MLTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.62 | ||
| Sortino ratioReturn per unit of downside risk | +3.47 | ||
| Omega ratioGain probability vs. loss probability | 1.52 | 1.25 | +0.27 |
| Calmar ratioReturn relative to maximum drawdown | 4.54 | -0.55 | +5.09 |
| Martin ratioReturn relative to average drawdown | 9.27 | -0.76 | +10.03 |
Loading charts...
Drawdowns
OMER vs. MLTX - Drawdown Comparison
The maximum OMER drawdown since its inception was -95.95%, which is greater than MLTX's maximum drawdown of -90.22%. Use the drawdown chart below to compare losses from any high point for OMER and MLTX.
Loading charts...
Drawdown Indicators
| OMER | MLTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.95% | -90.22% | -5.73% |
Max Drawdown (1Y)Largest decline over 1 year | -49.14% | -89.93% | +40.79% |
Max Drawdown (3Y)Largest decline over 3 years | -81.09% | -90.22% | +9.13% |
Max Drawdown (5Y)Largest decline over 5 years | -93.37% | -90.22% | -3.15% |
Max Drawdown (10Y)Largest decline over 10 years | -95.95% | — | — |
Current DrawdownCurrent decline from peak | -61.30% | -65.30% | +4.00% |
Average DrawdownAverage peak-to-trough decline | -48.52% | -29.48% | -19.04% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.03% | 64.55% | -40.52% |
Volatility
OMER vs. MLTX - Volatility Comparison
Omeros Corporation (OMER) has a higher volatility of 21.18% compared to MoonLake Immunotherapeutics (MLTX) at 19.22%. This indicates that OMER's price experiences larger fluctuations and is considered to be riskier than MLTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| OMER | MLTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 21.18% | 19.22% | +1.96% |
Volatility (6M)Calculated over the trailing 6-month period | 73.38% | 55.52% | +17.86% |
Volatility (1Y)Calculated over the trailing 1-year period | 187.42% | 116.84% | +70.58% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 134.91% | 91.48% | +43.43% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 111.00% | 86.43% | +24.57% |
Dividends
OMER vs. MLTX - Dividend Comparison
Neither OMER nor MLTX has paid dividends to shareholders.
Financials
OMER vs. MLTX - Financials Comparison
This section allows you to compare key financial metrics between Omeros Corporation and MoonLake Immunotherapeutics. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
OMER and MLTX have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
OMER has higher volatility (21.18%) compared to MLTX (19.22%). In terms of maximum drawdown, OMER dropped -95.95% vs MLTX's -90.22%.
OMER currently has the higher Sharpe Ratio (1.19 vs -0.42), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for OMER and MLTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer